Prenatal Depression Screening and Follow-Up (PND)*

***Developed with support from the California HealthCare Foundation (CHCF). CHCF works to ensure that people have access to the care they need, when they need it, at a price they can afford. Visit www.chcf org to learn more. Also supported by the Zoma Foundation.**

SUMMARY OF CHANGES TO HEDIS 2020

- First-year measure.

Description

The percentage of deliveries in which members were screened for clinical depression while pregnant and, if screened positive, received follow-up care. Two rates are reported.

1. *Depression Screening*: The percentage of deliveries in which members were screened for clinical depression during pregnancy using a standardized instrument.
2. *Follow-Up on Positive Screen*: The percentage of deliveries in which members received follow-up care within 30 days of screening positive for depression.

Measurement Period

January 1–December 31.

Clinical Recommendation Statement

The US Preventive Services Task Force (USPSTF) recommends screening for depression among adolescents and adults, including pregnant and postpartum women.

The American College of Obstetricians and Gynecologists (ACOG) recommends that clinicians screen patients at least once during pregnancy or the postpartum period for depression and anxiety symptoms using a standardized, validated tool.

The USPSTF and ACOG also recommend that screening be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment and appropriate follow-up.

References

American College of Obstetricians and Gynecologists. 2018. “Screening for Perinatal Depression. ACOG Committee Opinion No. 757.” *Obstetrics & Gynecology* 132(5):e208–12.

US Preventive Services Task Force. 2016. “Screening for Depression in Children and Adolescents: U.S. Preventive Services Task Force Recommendation Statement.” *Annals of Internal Medicine* 164:360–6.

US Preventive Services Task Force. 2016. “Screening for Major Depressive Disorder in Adults: US Preventive Services Task Force Recommendation Statement.” *Journal of the American Medical Association* 315(4):380–7.

Characteristics

Scoring	Proportion.
Type	Process.
Item count	Deliveries.
Stratification	1. Commercial* 2. Medicaid **Note that "Commercial" plans can be identified via the "Private Health Insurance" Direct Reference Code.*
Risk adjustment	None.
Improvement notation	A higher rate indicates better performance.
Guidance	**Allocation:** The member was enrolled with a medical benefit and no gaps in enrollment throughout the Participation Period. **Requirements:** • Each separate pregnancy episode ending in a delivery is counted in the initial population. A pregnancy episode ending in a delivery with multiple live births is counted once. • This measure requires the use of an age-appropriate screening instrument. The member's age is used to select the appropriate depression screening instrument. • Depression screening captured in health risk assessments or other types of health assessments is allowed if the questions align with a specific instrument that is validated for depression screening. For example, if a health risk assessment includes questions from the PHQ-2, it counts as screening if the member answered the questions and a total score is calculated. • Numerator 1: Depression Screening *Calculating gestational age*: Use gestational age at time of delivery and the delivery date to calculate the start of the pregnancy. If weeks of gestation at time of delivery is not available, the delivery is not compliant for the numerator.

Definitions

Pregnancy Episode	A pregnancy episode in which the delivery date occurs during the Measurement Period.
Depression Screening Instrument	A standard assessment instrument that has been normalized and validated for the appropriate patient population. Eligible screening instruments with thresholds for positive findings include:

Instruments for Adolescents (12–17 years)	Positive Finding
Patient Health Questionnaire (PHQ-9)®	Total Score ≥10
Patient Health Questionnaire Modified for Teens (PHQ-9M)®	Total Score ≥10
PRIME MD-PHQ2®	Total Score ≥3
Beck Depression Inventory-Fast Screen (BDI-FS)®*	Total Score ≥4
Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)	Total Score ≥17
Edinburgh Postnatal Depression Scale (EPDS)	Total Score ≥9
PROMIS Depression	Total Score (T Score) ≥52.5
Instruments for Adults (18+ years)	**Positive Finding**
Patient Health Questionnaire (PHQ-9)®	Total Score ≥10
PRIME MD-PHQ2®	Total Score ≥3
Beck Depression Inventory-Fast Screen (BDI-FS)®*	Total Score ≥4
Beck Depression Inventory (BDI-II)	Total Score ≥14
Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)	Total Score ≥17
Duke Anxiety-Depression Scale (DADS)®*	Total Score ≥30
Edinburgh Postnatal Depression Scale (EPDS)	Total Score ≥9
My Mood Monitor (M-3)®	Total Score ≥5
PROMIS Depression	Total Score (T Score) ≥52.5
Clinically Useful Depression Outcome Scale (CUDOS)	Total Score ≥11

*Proprietary; may be cost or licensing requirement associated with use.

Participation The identifiers and descriptors for each organization's coverage used to define members' eligibility for measure reporting. Allocation for reporting is based on eligibility during the Participation Period.

Participation Period 28 days prior to the delivery date through the delivery date.

Initial Population

Deliveries during the Measurement Period where the member also meets the criteria for Participation.

Exclusions

Exclusions

- Exclude deliveries that occurred at less than 37 weeks gestation.
- Exclude deliveries in which members were in hospice or using hospice services during the Measurement Period.

Depression Screening (Population Criteria 1)

Denominator 1 The Initial Population, minus Exclusions.

Numerator 1 Deliveries in which members had documentation of depression screening performed during pregnancy, using an age-appropriate standardized instrument.

- *Deliveries between January 1 and December 1 of the Measurement Period*: Screening should be performed between the pregnancy start date and the delivery date (including on the delivery date).
- *Deliveries Between December 2 and December 31 of the Measurement Period*: Screening should be performed between the pregnancy start date and December 1 of the Measurement Period.

Follow-Up on Positive Screen (Population Criteria 2)

Denominator 2 All deliveries from Numerator 1 with a positive finding for depression during pregnancy.

Numerator 2 Deliveries in which members received follow-up care on or up to 30 days after the date of the first positive screen (31 days total).

Any of the following on or up to 30 days after the first positive screen:

- An outpatient or telephone follow-up visit with a diagnosis of depression or other behavioral health condition.
- A depression case management encounter that documents assessment for symptoms of depression or a diagnosis of depression or other behavioral health condition.
- A behavioral health encounter, including assessment, therapy, collaborative care or medication management.
- A dispensed antidepressant medication.

or

- Receipt of an assessment on the same day and subsequent to the positive screen.
  - Documentation of additional depression screening indicating either no depression or no symptoms that require follow-up. For example, if the initial positive screen resulted from a PHQ-2 score, documentation of a negative finding from a subsequent PHQ-9 qualifies as evidence of follow-up.

Data Criteria (Element Level)

Value Sets:

- Diagnosis: Weeks of Gestation Less than 37 (2.16.840.1.113883.3.464.1004.1479)
- Diagnosis: 37 Weeks Gestation (2.16.840.1.113883.3.464.1004.1509)
- Diagnosis: 38 Weeks Gestation (2.16.840.1.113883.3.464.1004.1510)
- Diagnosis: 39 Weeks Gestation (2.16.840.1.113883.3.464.1004.1511)
- Diagnosis: 40 Weeks Gestation (2.16.840.1.113883.3.464.1004.1512)
- Diagnosis: 41 Weeks Gestation (2.16.840.1.113883.3.464.1004.1513)
- Diagnosis: 42 Weeks Gestation (2.16.840.1.113883.3.464.1004.1514)
- Diagnosis: 43 Weeks Gestation (2.16.840.1.113883.3.464.1004.1515)
- Encounter, Performed: Behavioral Health Encounter (2.16.840.1.113883.3.464.1004.1383)
- Encounter, Performed: Depression Case Management Encounter (2.16.840.1.113883.3.464.1004.1389)
- Encounter, Performed: Follow Up Visit (2.16.840.1.113883.3.464.1004.1385)
- Encounter, Performed: Hospice Encounter (2.16.840.1.113883.3.464.1004.1761)
- Intervention, Order: Hospice Intervention (2.16.840.1.113883.3.464.1004.1762)
- Intervention, Performed: Hospice Intervention (2.16.840.1.113883.3.464.1004.1762)
- Medication, Dispensed: Antidepressant Medication (2.16.840.1.113883.3.464.1004.1503)
- Procedure, Performed: Deliveries (2.16.840.1.113883.3.464.1004.1072)

Direct Reference Codes:

- Assessment, Performed: Beck Depression Inventory Fast Screen total score [BDI] (LOINC Code 89208-3)
- Assessment, Performed: Beck Depression Inventory II total score [BDI] (LOINC Code 89209-1)
- Assessment, Performed: Center for Epidemiologic Studies Depression Scale-Revised total score [CESD-R] (LOINC Code 89205-9)
- Assessment, Performed: Clinically Useful Depression Outcome Scale [CUDOS] (LOINC Code
- 90221-3)
- Assessment, Performed: Edinburgh Postnatal Depression Scale [EPDS] (LOINC Code 71354-5)
- Assessment, Performed: Final score [DADS] (LOINC Code 90853-3)
- Assessment, Performed: Length of gestation at birth (observable entity) (SNOMEDCT Code 412726003)
- Assessment, Performed: My Mood Monitor Total score [M3] (LOINC Code 71777-7)
- Assessment, Performed: Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] (LOINC Code 55758-7)
- Assessment, Performed: Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] (LOINC Code 44261-6)
- Assessment, Performed: Patient Health Questionnaire 9: Modified for Teens total score [Reported.PHQ.Teen] (LOINC Code 89204-2)
- Assessment, Performed: PROMIS 29 Depression score T score (LOINC Code 71965-8)
- Participation: Medicaid MEDICAID (SOP Code 2)
- Participation: PRIVATE HEALTH INSURANCE (SOP Code 5)
- Patient Characteristic Birthdate: Birth date (LOINC Code 21112-8)
- Symptom: Symptoms of depression (finding) (SNOMEDCT Code 394924000)

Attributes:

- Depression or Other Behavioral Health Condition (2.16.840.1.113883.3.464.1004.1501)

Data Elements for IDSS Reporting

Organizations that submit data to NCQA must provide the following data elements in a specified file.

Table PND-A: 1/2 Metadata Elements for Prenatal Depression Screening and Follow-Up

Metadata ID	Metadata Specification
MeasurementYear	Measurement year
CollectionMethod	Data collection methodology (electronic clinical data)

Table PND-B-1/2: Data Elements for Prenatal Depression Screening and Follow-Up

Indicator	Data Element	Data Source Logic
Depression Screening	Initial population	Report by data source
Follow-Up on Positive Screen	Exclusions	Report by data source
	Denominator	Summed over data sources
	Numerator	Report by data source

Postpartum Depression Screening and Follow-Up (PDS)*

***Developed with support from the California HealthCare Foundation (CHCF). CHCF works to ensure that people have access to the care they need, when they need it, at a price they can afford. Visit www.chcf org to learn more. Also supported by the Zoma Foundation.**

SUMMARY OF CHANGES TO HEDIS 2020

- First-year measure.

Description

The percentage of deliveries in which members were screened for clinical depression during the postpartum period, and if screened positive, received follow-up care. Two rates are reported.

1. *Depression Screening*: The percentage of deliveries in which members were screened for clinical depression using a standardized instrument during the postpartum period.
2. *Follow-Up on Positive Screen*: The percentage of deliveries in which members received follow-up care within 30 days of screening positive for depression.

Measurement Period

January 1–December 31.

Clinical Recommendation Statement

The U.S. Preventive Services Task Force (USPSTF) recommends screening for depression among adolescents and adults, including pregnant and postpartum women.

The American College of Obstetricians and Gynecologists (ACOG) recommends multiple postpartum visits no later than 12 weeks after birth that include a full assessment of psychological well-being, including screening for postpartum depression and anxiety with a validated instrument.

The American Academy of Pediatrics (AAP) recommends that pediatricians screen mothers for postpartum depression at the infant's one-, two-, four- and six-month visits.

The USPSTF and ACOG also recommend that screening be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment and appropriate follow-up.

References

American Academy of Pediatrics. Earls, M.F. 2010. "Committee on Psychosocial Aspects of Child and Family Health. Incorporating Recognition and Management of Perinatal and Postpartum Depression into Pediatric Practice." Pediatrics. 126(5):1032–9.

American College of Obstetricians and Gynecologists. 2018. "Screening for Perinatal Depression. ACOG Committee Opinion No. 757." Obstetrics & Gynecology. 132(5):e208-12.

U.S. Preventive Services Task Force. 2016. "Screening for Depression in Children and Adolescents: U.S. Preventive Services Task Force Recommendation Statement." Annals of Internal Medicine. 164:360–6.

U.S. Preventive Services Task Force. 2016. "Screening for Major Depressive Disorder in Adults: US Preventive Services Task Force Recommendation Statement." Journal of the American Medical Association. 315(4):380–7.

Characteristics

Scoring	Proportion.
Type	Process.
Item count	Deliveries.
Stratification	1. Commercial* 2. Medicaid **Note that "Commercial" plans can be identified via the "Private Health Insurance" Direct Reference Code.*
Risk adjustment	None.
Improvement notation	A higher rate indicates better performance.
Guidance	**Allocation:** The member was enrolled with a medical benefit and no gaps in enrollment throughout the Participation Period. **Requirements:** • Each separate pregnancy episode ending in a delivery is counted in the initial population. A pregnancy episode ending in a delivery with multiple live births is counted once. • This measure requires the use of an age-appropriate screening instrument. The age of the member is used in the selection of the appropriate depression screening instrument. • Depression screening captured in health risk assessments or other types of health assessments are allowed if the questions align with a specific instrument that is validated for depression screening. For example, if a health risk assessment includes questions from the PHQ-2, it counts as screening if the member answered the questions and a total score is calculated. • Numerator 1: do not count deliveries in the numerator if a depression screening was performed only in an acute inpatient setting during 1 to 84 days after the delivery date.

Definitions

Depression Screening Instruments

A standard assessment instrument that has been normalized and validated for the appropriate patient population. Eligible screening instruments with thresholds for positive findings include:

Instruments for Adolescents (12–17 years)	Positive Finding
Patient Health Questionnaire (PHQ-9)®	Total Score ≥10
Patient Health Questionnaire Modified for Teens (PHQ-9M)®	Total Score ≥10
PRIME MD-PHQ2®	Total Score ≥3
Beck Depression Inventory-Fast Screen (BDI-FS)®*	Total Score ≥4
Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)	Total Score ≥17
Edinburgh Postnatal Depression Scale (EPDS)	Total Score ≥9
PROMIS Depression	Total Score (T Score) ≥52.5
Instruments for Adults (18+ years)	**Positive Finding**
Patient Health Questionnaire (PHQ-9)®	Total Score ≥10
PRIME MD-PHQ2®	Total Score ≥3
Beck Depression Inventory-Fast Screen (BDI-FS)®*	Total Score ≥4
Beck Depression Inventory (BDI-II)	Total Score ≥14
Center for Epidemiologic Studies Depression Scale-Revised (CESD-R)	Total Score ≥17
Duke Anxiety-Depression Scale (DADS)®*	Total Score ≥30
Edinburgh Postnatal Depression Scale (EPDS)	Total Score ≥9
My Mood Monitor (M-3)®	Total Score ≥5
PROMIS Depression	Total Score (T Score) ≥52.5
Clinically Useful Depression Outcome Scale (CUDOS)**	Total Score ≥11

*Proprietary; may be cost or licensing requirement associated with use.

Participation

The identifiers and descriptors for each organization's coverage used to define members' eligibility for measure reporting. Allocation for reporting is based on eligibility during the Participation Period.

Participation Period

Delivery date through 60 days following the date of delivery.

Initial Population

Deliveries during September 8 of the year prior to the Measurement Period through September 7 of the Measurement Period where the member also meets the criteria for Participation.

Exclusions

Exclusions Exclude deliveries in which members were in hospice or using hospice services during the Measurement Period.

Depression Screening (Population Criteria 1)

Denominator 1 The Initial Population, minus Exclusions.

Numerator 1 Deliveries in which members had documentation of depression screening performed using an age-appropriate standardized instrument during 1 to 84 days following the date of delivery.

Follow-Up on Positive Screen (Population Criteria 2)

Denominator 2 All deliveries from Numerator 1 with a positive finding for depression during the 1 to 84 days following the date of delivery.

Numerator 2 Deliveries in which members received follow-up care on or up to 30 days after the date of the first positive screen (31 days total).

Any of the following on or up to 30 days after the first positive screen:

- An outpatient or telephone follow-up visit with a diagnosis of depression or other behavioral health condition.
- A depression case management encounter that documents assessment for symptoms of depression or a diagnosis of depression or other behavioral health condition.
- A behavioral health encounter, including assessment, therapy, collaborative care or medication management.
- A dispensed antidepressant medication.

or

- Receipt of an assessment on the same day and subsequent to the positive screen.
  - Documentation of additional depression screening indicating either no depression or no symptoms that require follow-up. For example, if the initial positive screen resulted from a PHQ-2 score, documentation of a negative finding from a subsequent PHQ-9 qualifies as evidence of follow-up.

Data Criteria (Element Level)

Value Sets:

- Encounter, Performed: Behavioral Health Encounter (2.16.840.1.113883.3.464.1004.1383)
- Encounter, Performed: Depression Case Management Encounter (2.16.840.1.113883.3.464.1004.1389)
- Encounter, Performed: Follow Up Visit (2.16.840.1.113883.3.464.1004.1385)
- Encounter, Performed: Hospice Encounter (2.16.840.1.113883.3.464.1004.1761)
- Intervention, Order: Hospice Intervention (2.16.840.1.113883.3.464.1004.1762)
- Intervention, Performed: Hospice Intervention (2.16.840.1.113883.3.464.1004.1762)
- Medication, Dispensed: Antidepressant Medication (2.16.840.1.113883.3.464.1004.1503)
- Procedure, Performed: Deliveries (2.16.840.1.113883.3.464.1004.1072)

Direct Reference Codes:

- Assessment, Performed: Beck Depression Inventory Fast Screen total score [BDI] (LOINC Code 89208-3)
- Assessment, Performed: Beck Depression Inventory II total score [BDI] (LOINC Code 89209-1)
- Assessment, Performed: Center for Epidemiologic Studies Depression Scale-Revised total score [CESD-R] (LOINC Code 89205-9)
- Assessment, Performed: Clinically Useful Depression Outcome Scale [CUDOS] (LOINC Code 90221-3)
- Assessment, Performed: Edinburgh Postnatal Depression Scale [EPDS] (LOINC Code 71354-5)
- Assessment, Performed: Final score [DADS] (LOINC Code 90853-3)
- Assessment, Performed: My Mood Monitor Total score [M3] (LOINC Code 71777-7)
- Assessment, Performed: Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] (LOINC Code 55758-7)
- Assessment, Performed: Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] (LOINC Code 44261-6)
- Assessment, Performed: Patient Health Questionnaire 9: Modified for Teens total score [Reported.PHQ.Teen] (LOINC Code 89204-2)
- Assessment, Performed: PROMIS 29 Depression score T score (LOINC Code 71965-8)
- Participation: MEDICAID (SOP Code 2)
- Participation: PRIVATE HEALTH INSURANCE (SOP Code 5)
- Patient Characteristic Birthdate: Birth date (LOINC Code 21112-8)
- Symptom: Symptoms of depression (finding) (SNOMEDCT Code 394924000)

Attributes:

- Depression or Other Behavioral Health Condition (2.16.840.1.113883.3.464.1004.1501)

Data Elements for IDSS Reporting

Organizations that submit data to NCQA must provide the following data elements in a specified file.

Table PDS-A: 1/2 Metadata Elements for Postpartum Depression Screening and Follow-Up

Metadata ID	Metadata Specification
MeasurementYear	Measurement year
CollectionMethod	Data collection methodology (electronic clinical data)

Table PDS-B-1/2: Data Elements for Postpartum Depression Screening and Follow-Up

Indicator	Data Element	Data Source Logic
Depression Screening	Initial population	Report by data source
Follow-Up on Positive Screen	Exclusions	Report by data source
	Denominator	Summed over data sources
	Numerator	Report by data source